文献速递乳腺MR

动态增强MRI纵向流入斜率变化预测乳腺癌新辅助化疗反应

Longitudinal wash-in slope changes on dynamic contrast enhancement MRI for predicting response to neoadjuvant chemotherapy in breast cancer.
PubMed 文献 · Eur Radiol · 2025-10-03

单中心回顾性研究纳入2016年1月至2022年12月接受新辅助化疗后手术的162例乳腺癌女性,于治疗前、2周期后、4周期后及治疗完成后行DCE-MRI测量肿瘤流入斜率百分比变化(ΔWIS),43例(26.5%)获病理完全缓解;ΔWIS在各时间点预测pCR的AUC为0.82~0.87,各时间点间无显著差异,4周期后ΔWIS在三阴性乳腺癌中AUC达0.96。

要点

  • ΔWIS在2周期、4周期及治疗完成后的AUC分别为0.82、0.86、0.87,各时间点间无显著差异。
  • 各时间点最佳阈值分别为-33%、-44%、-59%,敏感度74.4%~86.0%,特异度75.6%~80.7%。
  • 4周期后ΔWIS在三阴性乳腺癌中AUC为0.96,优于Luminal B型(AUC 0.83,p=0.04)。

核心结论

  • DCE-MRI测量的肿瘤WIS变化可动态监测新辅助化疗,纵向WIS变化能实时预测乳腺癌新辅助化疗后的病理反应,支持个体化治疗监测与决策。

研究设计与样本

  • 单中心回顾性研究,纳入2016年1月至2022年12月连续接受新辅助化疗后手术的乳腺癌女性162例(平均年龄51.9岁±9.1),所有患者于治疗前、2周期后、4周期后及治疗完成后行DCE-MRI,测量肿瘤WIS相对治疗前的百分比变化(ΔWIS),以病理完全缓解(pCR)为参考标准。

诊断标准与关键数值

  • ΔWIS预测pCR的AUC在2周期后为0.82(95%CI:0.73,0.91)、4周期后为0.86(95%CI:0.78,0.93)、治疗完成后为0.87(95%CI:0.8,0.93),各时间点间无显著差异(均p>0.05);各时间点最佳阈值分别为-33%、-44%、-59%,敏感度74.4%~86.0%,特异度75.6%~80.7%;4周期后ΔWIS在三阴性乳腺癌中AUC为0.96(95%CI:0.9,1),优于Luminal B型(AUC 0.83;95%CI:0.71,0.94;p=0.04)。

临床应用与阅片要点

  • 原文结论指出纵向WIS变化可实时预测新辅助化疗后的病理反应,支持个体化治疗监测与决策。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To determine whether wash-in slope (WIS) changes can predict pathologic complete response (pCR) following NAC in breast cancer.

MATERIALS AND METHODS: This single-center retrospective study included consecutive females with breast cancer who received NAC followed by surgery between January 2016 and December 2022. All patients received dynamic contrast-enhanced MRI (DCE-MRI) pretreatment, after 2 cycles, 4 cycles, and after completion of treatment. The percentage change in tumor WIS from that before treatment (ΔWIS) was measured at each time point. Predictive performance for pCR was assessed by using the area under the receiver operating characteristic curve (AUC) for the overall cohort and across molecular subtypes.

RESULTS: A total of 162 patients were included in this study (mean age, 51.9 years ± 9.1 [SD]), and 43 (26.5%) achieved pCR. Overall, ΔWIS demonstrated comparable performance in predicting pCR after 2 cycles (AUC, 0.82; 95% CI: 0.73, 0.91), 4 cycles (AUC, 0.86; 95% CI: 0.78, 0.93), and after completion of NAC (AUC, 0.87; 95% CI: 0.8, 0.93), with no significant differences observed (all p > 0.05). Utilizing optimal threshold values of -33%, -44%, and -59% at each time point, ΔWIS yielded sensitivities ranging from 74.4% to 86.0% and specificities ranging from 75.6% to 80.7%. In molecular subtype analysis, ΔWIS after 4 cycles exhibited excellent predictive performance for pCR in triple-negative breast cancers (AUC, 0.96; 95% CI: 0.9, 1), outperforming its performance in Luminal B tumors (AUC, 0.83; 95% CI: 0.71, 0.94; p = 0.04).

CONCLUSION: Tumor WIS changes from DCE-MRI could dynamically monitor neoadjuvant chemotherapy (NAC).

KEY POINTS: Question Currently, there is no widely accepted standard imaging biomarker for predicting pCR in breast cancer patients undergoing NAC. Findings WIS changes outperformed tumor size in predicting pCR at four time points during NAC, and showed comparable predictive performance across all time points. Clinical relevance Longitudinal changes in the WIS derived from dynamic contrast-enhanced MRI enable real-time prediction of pathologic response to NAC in patients with breast cancer, supporting personalized treatment monitoring and decision-making.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Li Y, Wang J, Guo J, et al. Longitudinal wash-in slope changes on dynamic contrast enhancement MRI for predicting response to neoadjuvant chemotherapy in breast cancer. Eur Radiol. 2025. PMID: 41042372. doi:10.1007/s00330-025-12042-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。